Telesis Bio, Inc. (TBIO)

USD 0.49

(-7.55%)

Total Liabilities Summary of Telesis Bio, Inc.

Telesis Bio, Inc.'s latest annual total liabilities in 2023 was 40.87 Million USD , up 17.46% from previous year.
Telesis Bio, Inc.'s latest quarterly total liabilities in 2024 Q1 was 41.68 Million USD , up 1.98% from previous quarter.
Telesis Bio, Inc. reported annual total liabilities of 34.79 Million USD in 2022, up 36.6% from previous year.
Telesis Bio, Inc. reported annual total liabilities of 25.47 Million USD in 2021, down -51.31% from previous year.
Telesis Bio, Inc. reported quarterly total liabilities of 41.68 Million USD for 2024 Q1, up 1.98% from previous quarter.
Telesis Bio, Inc. reported quarterly total liabilities of 52.54 Million USD for 2023 Q1, up 51.0% from previous quarter.

Annual Total Liabilities Chart of Telesis Bio, Inc. (2023 - 2016)

Historical Annual Total Liabilities of Telesis Bio, Inc. (2023 - 2016)

Year	Total Liabilities	Total Liabilities Growth
2023	40.87 Million USD	17.46%
2022	34.79 Million USD	36.6%
2021	25.47 Million USD	-51.31%
2020	52.32 Million USD	13.09%
2019	46.26 Million USD	-71.5%
2018	162.35 Million USD	-44.41%
2017	292.06 Million USD	19.62%
2016	244.15 Million USD	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	42.78 Million USD	2.64%
2024 Q1	41.68 Million USD	1.98%
2023 Q1	52.54 Million USD	51.0%
2023 Q4	40.87 Million USD	-30.18%
2023 Q2	86.61 Million USD	64.84%
2023 FY	40.87 Million USD	17.46%
2023 Q3	58.54 Million USD	-32.41%
2022 Q3	34.83 Million USD	6.97%
2022 Q4	34.79 Million USD	-0.11%
2022 FY	34.79 Million USD	36.6%
2022 Q1	33.03 Million USD	29.68%
2022 Q2	32.56 Million USD	-1.42%
2021 Q3	21.73 Million USD	-9.37%
2021 Q1	64.01 Million USD	22.36%
2021 FY	25.47 Million USD	-51.31%
2021 Q4	25.47 Million USD	17.21%
2021 Q2	23.98 Million USD	-62.54%
2020 Q2	182.88 Million USD	12.5%
2020 Q4	52.32 Million USD	-90.36%
2020 Q3	542.96 Million USD	196.89%
2020 Q1	162.57 Million USD	-11.0%
2020 FY	52.32 Million USD	13.09%
2019 Q3	167.94 Million USD	-10.12%
2019 Q1	182.62 Million USD	12.49%
2019 FY	46.26 Million USD	-71.5%
2019 Q4	182.66 Million USD	8.77%
2019 Q2	186.85 Million USD	2.31%
2018 Q1	101.86 Million USD	-65.12%
2018 FY	162.35 Million USD	-44.41%
2018 Q4	162.35 Million USD	-7.32%
2018 Q3	175.17 Million USD	-42.52%
2018 Q2	304.74 Million USD	199.16%
2017 FY	292.06 Million USD	19.62%
2017 Q4	292.06 Million USD	0.0%
2016 FY	244.15 Million USD	0.0%

Peer Total Liabilities Comparison of Telesis Bio, Inc.

Name	Total Liabilities	Total Liabilities Difference
Acutus Medical, Inc.	54.83 Million USD	25.467%
Biotricity, Inc.	35.91 Million USD	-13.791%
Cell MedX Corp.	872.57 Thousand USD	-4584.171%
Dynatronics Corporation	11.78 Million USD	-246.966%
Nemaura Medical Inc.	26.37 Million USD	-54.954%
PetVivo Holdings, Inc.	2.42 Million USD	-1582.501%
RetinalGenix Technologies Inc.	1.4 Million USD	-2807.428%
Sonendo, Inc.	49.74 Million USD	17.828%
Talis Biomedical Corporation	29.22 Million USD	-39.861%
Viveve Medical, Inc.	10.84 Million USD	-276.814%